Low incidence of endometrial hyperplasia with acceptable bleeding patterns in women taking sequential hormone replacement therapy with dydrogesterone

Gynecological Endocrinology

Volumn 14, Issue 4, 2000, Pages 275-281

  Bergeron, C ^a   Fox, H ^a  

^a LABORATOIRE CERBA   (France)

Author keywords

Dydrogesterone; Endometrium; Hyperplasia; Sequential hormone replacement therapy

Indexed keywords

DYDROGESTERONE; DYDROGESTERONE PLUS ESTRADIOL; ESTRADIOL; SEQUENTIAL CONTRACEPTIVE AGENT;

ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MENSTRUAL CYCLE; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; UTERUS BLEEDING;

EID: 0033791998     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513590009167694     Document Type: Article

References (27)

1. The benefits and risks of hormone replacement therapy: An epidemiologic overview
2. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
3. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues
4. Risk of localised and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens
5. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer
6. The effects of estrogens and progestogens on the endometrium
7. Effect of long-term therapy with estrogen and progesterone on the endometrium of post-menopausal women
8. Endomettial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone
9. Effect of dydrogesterone on the oestrogenized postmenopausal endometrium
10. Endometrial responses, side-effects and bleeding patterns in postmenopausal women using various doses of dydrogesterone in combination with conjugated oestrogens
11. Changes in the withdrawal bleeding pattern and enometrial histology during 17β-oestradioldydrogesterone therapy in post-menopausal women: A 2-year prospective study
12. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17β oestradiol
13. Dydrogesterone has no peripheral (anti)-androgenic properties
14. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone
15. Safety of progestins: Effects of dydrogesterone on blood lipids
16. Progestins: A review of safety and tolerance in long-term administration
17. Women's expectations and acceptance of cyclic induced HRT bleeds
18. An objective and subjective assessment of uterine blood loss in postmenopausal women on hormone replacement therapy
19. Compliance considerations with estrogen replacement withdrawal bleeding and other factors
20. Compliance with hormone replacement therapy after screening for postmenopausal osteoporosis
21. Effects on hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin intervention trial
22. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy
23. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
24. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens
25. Comparison of two equine oestrogen-dydrogesterone regimens in the climacteric
26. A first study to compare two dosages of dydrogesterone in opposing the 50 mg oestradiol implant
27. Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone